Print Page | Sign In | Join
News & Press: Industry Events

Vycellix’s CEO to Present Novel Approaches to Adoptive Cancer Immunotherapy at Innate Killer Summit

Monday, May 2, 2016   (0 Comments)
Share |

Vycellix’s CEO to Present Novel Approaches to Adoptive Cancer Immunotherapy at Innate Killer Summit

New Products Enhance Genetic Modification of Lymphocytes and Significantly Amplify Cancer Killing Capacity

SARASOTA, Fla.--()--Vycellix, Inc., a privately-held biotechnology company advancing novel products capable of optimizing human immune response against disease with a focus on cancers, today announced that its CEO, Evren Alici, M.D., Ph.D., will present at the Innate Killer Summit 2016 to be held in San Diego, CA, May 16-18. The Company expects to initially advance its technology for the treatment of hematological malignancies and sarcomas.

Dr. Alici will present two sessions at the Summit including a talk titled, “Screening for the Best Response for Adoptively Transferred NK-cells” and a half-day workshop titled, “Cell Expansion Methodologies for Enhanced Efficacy”. Dr. Alici serves as the Head of the Gene & Cell Therapy Group, Department of Medicine, Division of Hematology, Karolinska Institutet, Stockholm, Sweden and as Visiting Research Professor at the NSU Cell Therapy Institute, Ft. Lauderdale, Florida.

Vycellix’s pre-IND product pipeline includes the novel molecules VY-OZ and VY-X which have demonstrated unrivaled enhancement of T-cells and natural killer cells (NK-cells). These products have shown to be capable of: delivering optimal and cost-effective gene modification; rapidly increasing in vivo and ex vivo immune response, and; yielding unprecedented amplification of killing capacity for cytotoxic lymphocytes.

To schedule a meeting with Vycellix at the Innate Killer Summit in San Diego, May 16-18, or at the ASCO Annual Meeting, June 3-7 in Chicago, please contact Douglas Calder, President, at

About Vycellix, Inc.:

Vycellix is advancing its proprietary pipeline of novel immunomodulators as therapeutics for cancers and infectious disease, as well as establishing these products as platform technology for the efficient, cost-effective modulation of cell and gene therapies. For more information, please visit:


Investor/Media Relations:
Vycellix, Inc.
Douglas W. Calder,772-418-6302

About BioFlorida

BioFlorida represents 6,200 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ 87,000 Floridians.


Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.


NEW regional sponsorship opportunities available.